Crinetics Pharmaceuticals Inc
$ 47.42
0.94%
04 Dec - close price
- Market Cap 4,458,019,000 USD
- Current Price $ 47.42
- High / Low $ 48.62 / 46.63
- Stock P/E N/A
- Book Value 11.34
- EPS -4.53
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.44 %
- 52 Week High 60.34
- 52 Week Low 24.10
About
Crinetics Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing groundbreaking therapies for rare endocrine diseases and associated tumors. The company possesses a robust pipeline of innovative drug candidates, targeting significant unmet needs in the endocrine disorder market with both oral and targeted therapies. Crinetics is committed to advancing research and development efforts, positioning itself as a leader in specialized endocrine treatments, and striving to improve patient outcomes while transforming treatment paradigms in this vital healthcare sector.
Analyst Target Price
$80.21
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 | 2023-05-04 | 2023-02-28 |
| Reported EPS | -1.38 | -1.23 | -1.04 | -0.88 | -0.96 | -0.94 | -0.93 | -0.9 | -1.01 | -0.94 | -0.85 | -0.84 |
| Estimated EPS | -1.25 | -1.1 | -0.9523 | -0.8919 | -0.91 | -0.86 | -0.81 | -0.86 | -0.86 | -0.86 | -0.81 | -0.82 |
| Surprise | -0.13 | -0.13 | -0.0877 | 0.0119 | -0.05 | -0.08 | -0.12 | -0.04 | -0.15 | -0.08 | -0.04 | -0.02 |
| Surprise Percentage | -10.4% | -11.8182% | -9.2093% | 1.3342% | -5.4945% | -9.3023% | -14.8148% | -4.6512% | -17.4419% | -9.3023% | -4.9383% | -2.439% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRNX
2025-10-15 21:30:10
The "Hyperparathyroidism Pipeline 2025" report by DelveInsight highlights significant advancements in the treatment landscape, with over 25 pharmaceutical and biotech companies developing more than 30 therapeutic candidates. Key players like Shanghai Hengrui Pharmaceutical, Shaanxi Micot Technology, and Crinetics Pharmaceuticals are actively working on new therapies. Noteworthy pipeline candidates include SHR6508 (Phase III by Shanghai Hengrui) and MT1013 (Phase II by Shaanxi Micot), while Parsabiv (etelcalcetide) recently received approval for secondary hyperparathyroidism in dialysis patients.
2025-10-15 00:30:47
Crinetics Pharmaceuticals has recently formed a Golden Cross, indicating a potential bullish shift in its stock momentum. While daily and weekly technical indicators are bullish, the monthly MACD shows a mildly bearish trend, suggesting mixed signals in the longer term. Despite a one-year decline, the company has shown a significant three-year performance increase, attracting investor interest.
2025-10-13 14:42:44
Crinetics Pharmaceuticals, Inc. announced inducement grants consisting of non-qualified stock options for 78,975 shares and 54,475 restricted stock units (RSUs) to 20 new non-executive employees. These grants, made on October 10, 2025, are intended to induce employment, in accordance with Nasdaq Listing Rule 5635(4). The stock options have an exercise price of $44.93 per share and, along with the RSUs, will vest over four years, subject to continued employment.
2025-10-06 16:05:00
Crinetics Pharmaceuticals announced it will report its third-quarter 2025 financial results on Thursday, November 6, 2025, after market close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. This announcement includes details for participating in the conference call and provides background on Crinetics Pharmaceuticals and its product pipeline.
2025-02-27 16:05:00
Crinetics Pharmaceuticals announced its financial results for the fourth quarter and full year ended December 31, 2024, highlighting significant progress including the NDA acceptance for paltusotine in acromegaly and strong commercial preparations. The company expects to initiate four late-stage trials in 2025 and reported a robust financial position with $1.4 billion in cash, providing a runway into 2029. Key appointments to the leadership team were also made to support upcoming milestones and growth.
2024-12-16 00:00:00
Crinetics Pharmaceuticals, Inc. announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the commercial strategy for the potential launch of paltusotine and pre-commercialization activities for the company's pipeline. She brings over 20 years of global pharmaceutical and biotech experience to Crinetics.
